INDUSTRY DYNAMICS FAVORABLE FOR THE GROWTH
The most potent catalyst for the Indian CDMO sector is the implementation of the United States BIOSECURE Act. This legislation aims to restrict US entities from utilizing federal funds to procure biotechnology equipment or services from specific foreign adversarial companies, citing national security concerns. The Act explicitly targets prominent Chinese CDMOs and genomics firms, including WuXi AppTec, WuXi Biologics, BGI, MGI, and Complete Genomics. China currently commands a 30% to 35% share of the global API and CDMO market, representing roughly US$ 60 billion to US$ 75 billion in annual revenue. So even a fraction shift in the market share to India, should benefit the Indian companies.
Global pharmaceutical innovators and large generic conglomerates are under immense pressure to decouple their supply chains from Chinese manufacturers due to geopolitical tensions and environmental disruptions. By offering a fully localized, USFDA-compliant manufacturing ecosystem rooted in India, Viyash secures long-term, high-volume contracts by guaranteeing supply security to its partners
BACKWARD INTEGRATION AND PRODUCT AND GEOGRAPHIC EXPANSION TO DRIVE GROWTH
While near-term growth is supported by existing capacity, backward integration and volume optimization, the true structural inflection in Viyash’s earnings profile is back-ended and tied to its complex R&D engine. The company has deliberately pivoted away from commoditized, high-volume generic APIs toward high-barrier, complex therapeutic areas such as oncology and central nervous system (CNS) treatments. Developing these highly potent active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs requires specialized containment infrastructure (OEB-4/5 levels) and a long gestation period, typically taking five to seven years from development to commercialization. The company has guided for a revenue of $1bn by 2032 and a $150-200 mn companion ambition for the long term with high potency API launches around 2029, while it is confident to achieve Rs.4000 cr in FY27, with improving margins due to focus on high potent APIs.
OUTLOOK AND VALUATION
We expect the company’s topline to grow at a CAGR of ~15% to Rs. 5,138 cr in FY26-29E. On conservative basis, we have expected EBITDA margin to remain at healthy level, 19%. Hence, with an expected PAT margin of 9% in FY29E, we expect the PAT and EPS to be at Rs. 466 cr and Rs. 10.7 respectively. We have assigned a P/E multiple of 30x to arrive at a price target of Rs. 314 which provides an upside of ~35% within 18 to 24 months from the current market price of Rs.232.